RAC 0.55% $1.82 race oncology ltd

Ann: Race Develops Improved IV Formulation of Zantrene, page-16

  1. 2,841 Posts.
    lightbulb Created with Sketch. 2891
    great insight, wasn’t aware of home infusion this is very interesting. Oral formulation is in the works so should provide holistic patient options.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.